WHY SHOULD YOU ATTEND?
Gain a refresher/update on the technical aspects specific to the regulation of rDNA derived medicinal products
Improve your knowledge of the differences between the regulation of rDNA products and conventional small molecule drugs
Compare experiences with delegates from across Europe
* Please note – the seminar assumes a scientific background and a basic knowledge of drug regulatory affairs
WHO SHOULD ATTEND?
Life scientists moving into biotech regulatory affairs
Technical and scientific decision makers in biotech start up operations
Those with a life science background in the financial sector involved in due diligence or regulatory portfolio
Those from small molecule backgrounds transferring to biotech product regulatory affairs
CHAIRMAN
Dr Mark Richardson - Richardson Associates Regulatory Affairs Ltd
Gain a refresher/update on the technical aspects specific to the regulation of rDNA derived medicinal products
Improve your knowledge of the differences between the regulation of rDNA products and conventional small molecule drugs
Compare experiences with delegates from across Europe
* Please note – the seminar assumes a scientific background and a basic knowledge of drug regulatory affairs
WHO SHOULD ATTEND?
Life scientists moving into biotech regulatory affairs
Technical and scientific decision makers in biotech start up operations
Those with a life science background in the financial sector involved in due diligence or regulatory portfolio
Those from small molecule backgrounds transferring to biotech product regulatory affairs
CHAIRMAN
Dr Mark Richardson - Richardson Associates Regulatory Affairs Ltd
